$OGEN
ORAGENICS INC

2024 Q3 Form 10-Q Financial Statement

#000149315224031000 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $13.16K
YoY Change -56.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.399M $1.116M
YoY Change 25.4% 6.84%
% of Gross Profit
Research & Development $879.0K $906.8K $2.007M
YoY Change 14.26% -54.81% -33.84%
% of Gross Profit
Depreciation & Amortization $0.00 $11.31K
YoY Change -100.0% 8.96%
% of Gross Profit
Operating Expenses $2.437M $2.306M $3.122M
YoY Change 15.96% -26.15% -23.42%
Operating Profit -$2.437M -$2.306M -$3.109M
YoY Change 16.37% -25.84% -13.74%
Interest Expense $910.00 $843.00
YoY Change 7.95% -94.21%
% of Operating Profit
Other Income/Expense, Net -$25.59K $910.00 $58.73K
YoY Change -131.38% -98.45% -49043.33%
Pretax Income -$2.463M -$2.305M -$3.051M
YoY Change 22.36% -24.44% -24.35%
Income Tax
% Of Pretax Income
Net Earnings -$2.463M -$2.305M -$3.051M
YoY Change 22.36% -24.44% -24.35%
Net Earnings / Revenue -23175.46%
Basic Earnings Per Share -$0.38 -$0.51 -$1.51
Diluted Earnings Per Share -$0.38 -$0.51 -$1.51
COMMON SHARES
Basic Shares Outstanding 5.581M shares 4.481M shares 2.025M shares
Diluted Shares Outstanding 6.528M shares 4.529M shares 2.025M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.349M $6.474M
YoY Change -79.17% -63.77%
Cash & Equivalents $3.144M $1.349M $6.474M
Short-Term Investments
Other Short-Term Assets $270.3K $1.612M
YoY Change -83.23% 1472.54%
Inventory
Prepaid Expenses $386.0K $248.3K $1.600M
Receivables
Other Receivables $13.16K
Total Short-Term Assets $4.113M $1.619M $8.099M
YoY Change -47.36% -80.01% -54.93%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $98.46K
YoY Change -100.0% -80.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.091M $17.94K
YoY Change 5979.99%
Total Long-Term Assets $1.091M $1.091M $365.7K
YoY Change 1178.18% 198.3% -26.15%
TOTAL ASSETS
Total Short-Term Assets $4.113M $1.619M $8.099M
Total Long-Term Assets $1.091M $1.091M $365.7K
Total Assets $5.204M $2.710M $8.464M
YoY Change -34.12% -67.99% -54.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.180M $590.6K
YoY Change 99.88% -53.85%
Accrued Expenses $65.66K $181.0K $334.4K
YoY Change 45.02% -45.89% 84.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.383M $1.141M
YoY Change 21.21% -21.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $65.75K
YoY Change -69.75%
Total Long-Term Liabilities $0.00 $65.75K
YoY Change -100.0% -69.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.383M $1.141M
Total Long-Term Liabilities $0.00 $65.75K
Total Liabilities $2.127M $1.383M $1.207M
YoY Change 51.67% 14.61% -28.06%
SHAREHOLDERS EQUITY
Retained Earnings -$213.4M -$211.0M -$191.5M
YoY Change 10.32% 10.19%
Common Stock $9.388K $5.581K $2.025K
YoY Change 268.3% 175.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.078M $1.326M $7.257M
YoY Change
Total Liabilities & Shareholders Equity $5.204M $2.710M $8.464M
YoY Change -34.12% -67.99% -54.16%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$2.463M -$2.305M -$3.051M
YoY Change 22.36% -24.44% -24.35%
Depreciation, Depletion And Amortization $0.00 $11.31K
YoY Change -100.0% 8.96%
Cash From Operating Activities -$1.545M -$2.577M
YoY Change -40.06% -23.83%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 821.2K -107.9K
YoY Change -861.11% -11.7%
NET CHANGE
Cash From Operating Activities -1.545M -2.577M
Cash From Investing Activities 0.000
Cash From Financing Activities 821.2K -107.9K
Net Change In Cash -723.4K -2.685M
YoY Change -73.05% -23.41%
FREE CASH FLOW
Cash From Operating Activities -$1.545M -$2.577M
Capital Expenditures $0.00
Free Cash Flow -$2.577M
YoY Change -23.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
270334 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1618955 usd
CY2024Q2 OGEN Prepaid Research And Development Expense Noncurrent
PrepaidResearchAndDevelopmentExpenseNoncurrent
1090750 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9811 usd
CY2024Q2 us-gaap Assets
Assets
2709705 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1383309 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9811 usd
CY2024Q2 us-gaap Liabilities
Liabilities
1383309 usd
CY2024Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2023Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
1592723 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5580693 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5580693 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3080693 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3080693 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
5581 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
210702269 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210974177 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1326396 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2709705 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001174940
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q2 OGEN Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisable
shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32188
dei Entity Registrant Name
EntityRegistrantName
ORAGENICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-3410522
dei Entity Address Address Line1
EntityAddressAddressLine1
1990 Main Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 750
dei Entity Address City Or Town
EntityAddressCityOrTown
Sarasota
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34236
dei City Area Code
CityAreaCode
813
dei Local Phone Number
LocalPhoneNumber
286-7900
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OGEN
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5580693 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1348621 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13163 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30187 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
906779 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1399221 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
2306000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2306000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
6405 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1803 usd
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
621 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1745 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3692 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6572 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
910 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2305090 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2305090 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.04
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4529045 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4529045 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2024766 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2024766 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4012561 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4012561 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1941858 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1941858 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3168154 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
69344 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1838601 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2450833 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2625266 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
58220 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
948000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2305090 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1326396 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13009302 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
79966 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2844837 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10244431 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10244431 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63628 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3050586 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7257473 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7257473 usd
us-gaap Net Income Loss
NetIncomeLoss
-4755923 usd
us-gaap Net Income Loss
NetIncomeLoss
-5895423 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
22606 usd
us-gaap Share Based Compensation
ShareBasedCompensation
127564 usd
us-gaap Share Based Compensation
ShareBasedCompensation
143594 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
13163 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-111939 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1232949 usd
OGEN Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-9811 usd
OGEN Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-98184 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-92358 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-274070 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9811 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4608778 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4685323 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
312703 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
267640 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2786601 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2473898 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-267640 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2134880 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4952963 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3483501 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11426785 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1348621 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6473822 usd
us-gaap Interest Paid Net
InterestPaidNet
8888 usd
us-gaap Interest Paid Net
InterestPaidNet
3347 usd
us-gaap Net Income Loss
NetIncomeLoss
-4755923 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4608778 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210974177 usd
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2600000 shares
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3200000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_ziwTfGVxt7Gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zxJMYS01Pku">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the condensed consolidated financial statements are estimates for research and development expenses and related prepaid and accrued expenses, which are based on the percentage of completion of the Company’s contracts with Contract Research Organizations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
248309 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
334940 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
22025 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
47333 usd
CY2024Q2 OGEN Prepaid Research And Development Expense Noncurrent
PrepaidResearchAndDevelopmentExpenseNoncurrent
1090750 usd
CY2023Q4 OGEN Prepaid Research And Development Expense Noncurrent
PrepaidResearchAndDevelopmentExpenseNoncurrent
1090750 usd
CY2024Q2 OGEN Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
1361084 usd
CY2023Q4 OGEN Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
1473023 usd
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1180429 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1244947 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
180955 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
222739 usd
CY2024Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
21925 usd
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
7981 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1383309 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1475667 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
312703 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
312703 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
260995 shares
CY2023Q4 OGEN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
82.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
125000 shares
OGEN Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
1.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
37168 shares
OGEN Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice
72.24
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
348827 shares
CY2024Q2 OGEN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
52.02
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
348827 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
244733 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.17
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M15D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
17146 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
28.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4667 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.52
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
222920 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.72
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M14D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
186370 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
22.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y25D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
58220 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
63628 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
127564 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
143594 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
160927 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
6000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
3.37

Files In Submission

Name View Source Status
0001493152-24-031000-index-headers.html Edgar Link pending
0001493152-24-031000-index.html Edgar Link pending
0001493152-24-031000.txt Edgar Link pending
0001493152-24-031000-xbrl.zip Edgar Link pending
ex10-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
ogen-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ogen-20240630_cal.xml Edgar Link unprocessable
ogen-20240630_def.xml Edgar Link unprocessable
ogen-20240630_lab.xml Edgar Link unprocessable
ogen-20240630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending